CClinicalTrials.gg
RecruitingNCT06183528Updated Nov 19, 2025

Effects of Pericapsular Nerve Group Block on Postoperative Recovery for Total Hip Arthroplasty

An interventional study of Pericapsular Nerve Group (PENG) Block in Analgesia and Postoperative Pain, Acute, sponsored by Umraniye Education and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Umraniye Education and Research Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Study summary

The hypothesis of this study is that patients who undergo PENG block in before Total Hip Artroplasthy (THA) surgery with spinal anesthesia will have reduced postoperative pain scores, less need for opioid analgesics and earlier mobilisation.

Read the detailed description

This prospective randomised controlled study included a total of 60 patients aged 40-85 years who underwent THA surgery under spinal anaesthesia. Patients were divided into two groups as PENG block (n:30) and non-PENG block (n:30). PENG block was placed in the fascial plane between the pseudotendon and pubic ramus with USG in-plane technique, 20 ml of 0.5% bupivacaine was administered and surgery was initiated. The primary outcome of the study was to investigate the effect of preoperative PENG block application on postoperative pain, opioid requirement, mobilisation time, hip joint patency and length of hospital stay in patients undergoing THA surgery. The secondary outcome was to investigate the effect of PENG block on perioperative haemodynamics and postoperative side effects.

For multimodal analgesia, 10 ml 0.5% bupivacaine + 10 ml 2% lidocaine is infiltrated into the surgical wound incision line by the surgical team at the end of surgery. After tramadol 50 mg loading with PCA device, a basal rate of 5-10 mg/hour (20 mg bolus dose + 30 minutes lock time) is given with paracetamol 10 mg/kg iv (8 hours interval).

02

Conditions studied

  • Analgesia
  • Postoperative Pain, Acute

Keywords

  • Multimodal analgesia
  • pericapsular nerve group block
  • total hip arthroplasty
  • spinal anesthesia
03

In context

Agnosia

1,190 studies on the registry are indexed under Agnosia; 507 are open to participants now.

This study's planned enrollment of 60 is below the median of 77 across 1,023 interventional studies indexed under Agnosia.

Browse Agnosia studies →

Lead sponsor

Umraniye Education and Research Hospital is the lead sponsor of 60 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • THA performed by posterior approach
  • 40-85 age range
  • ASA 1-3

Exclusion criteria

Exclusion Criteria:

Under 40 years of age, over 85 years of age,

  • ASA 4 and above,
  • Cognitive impairment (Alzheimer's disease, dementia, delirium etc.),
  • Hip fracture,
  • Application site infection,
  • Allergy to local anaesthetic agents,
  • Patients are non-consenting patients.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    PENG group

    PENG block was placed in the fascial plane between the pseudotendon and pubic ramus with USG in-plane technique, 20 ml of 0.5% bupivacaine was administered after spinal anaesthesia.

    Procedure: Pericapsular Nerve Group (PENG) Block

  • Placebo comparator
    non-PENG group

    group non-PENG, surgery was started without PENG block after spinal anaesthesia.

    Procedure: Pericapsular Nerve Group (PENG) Block

Interventions

  • ProcedurePericapsular Nerve Group (PENG) Block

    With ultrasonography-guided PENG block, the femoral, obturator and accessory obturator nerve branches that provide sensory innervation of the anterior surface of the hip joint capsule are blocked .

06

What researchers measure

Primary outcomes

  1. postoperative pain score

    VAS pain score

    Time frame: recovery room 30 min, 12., 24. and 48. hours in the postoperative period

  2. mobilisation time

    walking 5 steps with walker

    Time frame: 24 -48 hours

  3. hip joint patency

    Measurement of joint movement angle with goniometer (angle)

    Time frame: 24. hours

  4. total opioid consumption

    Tramadol total usage (mg)

    Time frame: 48 hours

Secondary outcomes

  1. PENG block side effects

    motor block, nausea, vomiting, anaphylaxis, nerve damage

    Time frame: The first 48 hours after performing the PENG block

  2. Perioperative haemodynamic data

    heart rate, mean arterial pressure

    Time frame: T1: 30 minutes (min) after spinal anesthesia, T2: at the end of the surgical procedure, T3: at 30 minutes after recovery

  3. length of hospital stay

    hospitalization and discharge time for surgery

    Time frame: day

07

Study locations

1 of 1 sites recruiting
  • UmraniyeERH
    Istanbul, Umraniye 34734, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06183528
Lead sponsor
Umraniye Education and Research Hospital
Responsible party
Zeliha Alicikus (Ass prof, Umraniye Education and Research Hospital) — Principal investigator
First posted
Dec 27, 2023
Start date
Sep 1, 2023
Primary completion
Oct 10, 2024
Completion
Dec 30, 2025 (estimated)
Last update
Nov 19, 2025

Study contacts

zeliha tuncel, ass prof
Contact
zelihalara@yahoo.com
+905053577483
hale arkan tuna, specialist dr
Contact
halearkan@yahoo.com.tr
+905303705619
zeliha tuncel
study director · Ümraniye Training and Education hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion